Review

taxifolin (MedChemExpress)

Name: taxifolin
Brand: MedChemExpress
Rating: 94 (25 reviews)

MedChemExpress is a verified supplier

MedChemExpress manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

MedChemExpress taxifolin

Prediction of intersection targets shared by colitis and drugs (Berberine and <t>Taxifolin)</t> and biological function analysis. (A) The molecular targets of Berberine and Taxifolin and the molecular targets of colitis were searched through online databases. The Venn diagram was used to intersect the molecular targets of Berberine, Taxifolin and colitis. (B) The PPI was used to perform interaction analysis on 37 molecules. (C) The 37 molecular targets were visualized and clustered using Cytoscape software. (D) GO enrichment analysis was performed on 37 molecules. (E) KEGG enrichment analysis was performed on 37 molecules. (F) Re-clustering by MCODE (degree>5) in Cytoscape software. (G) The top 10 molecular targets among 37 molecules were screened using the EPC statistical method in Cytoscape software. (H) The top 10 molecular targets among 37 molecules were screened using the MCC statistical method in Cytoscape software.

Taxifolin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 25 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/taxifolin/product/MedChemExpress
Average 94 stars, based on 25 article reviews

taxifolin - by Bioz Stars, 2026-02

94/100 stars

Images

1) Product Images from "Berberine-taxifolin co-administration attenuates inflammatory response and intestinal barrier injury via nf-κB/NLRP3 suppression in colitis"

Article Title: Berberine-taxifolin co-administration attenuates inflammatory response and intestinal barrier injury via nf-κB/NLRP3 suppression in colitis

Journal: Frontiers in Immunology

doi: 10.3389/fimmu.2025.1725084

Prediction of intersection targets shared by colitis and drugs (Berberine and Taxifolin) and biological function analysis. (A) The molecular targets of Berberine and Taxifolin and the molecular targets of colitis were searched through online databases. The Venn diagram was used to intersect the molecular targets of Berberine, Taxifolin and colitis. (B) The PPI was used to perform interaction analysis on 37 molecules. (C) The 37 molecular targets were visualized and clustered using Cytoscape software. (D) GO enrichment analysis was performed on 37 molecules. (E) KEGG enrichment analysis was performed on 37 molecules. (F) Re-clustering by MCODE (degree>5) in Cytoscape software. (G) The top 10 molecular targets among 37 molecules were screened using the EPC statistical method in Cytoscape software. (H) The top 10 molecular targets among 37 molecules were screened using the MCC statistical method in Cytoscape software.

Figure Legend Snippet: Prediction of intersection targets shared by colitis and drugs (Berberine and Taxifolin) and biological function analysis. (A) The molecular targets of Berberine and Taxifolin and the molecular targets of colitis were searched through online databases. The Venn diagram was used to intersect the molecular targets of Berberine, Taxifolin and colitis. (B) The PPI was used to perform interaction analysis on 37 molecules. (C) The 37 molecular targets were visualized and clustered using Cytoscape software. (D) GO enrichment analysis was performed on 37 molecules. (E) KEGG enrichment analysis was performed on 37 molecules. (F) Re-clustering by MCODE (degree>5) in Cytoscape software. (G) The top 10 molecular targets among 37 molecules were screened using the EPC statistical method in Cytoscape software. (H) The top 10 molecular targets among 37 molecules were screened using the MCC statistical method in Cytoscape software.

Techniques Used: Software

Berberine and Taxifolin combined administration increased the protective effect against colitis in mice. (A) Body weight changes of mice after modeling and drug administration. (B–I) Body weight changes of mice at modeling and drug administration 7 th day to 14 th day. (J, K) The colon length changes in different treatment groups. (L) Disease activity index in different treatment groups. (M, N) The H&E staining and Histological scores in different treatment groups. *p <0.05; **p <0.01; ***p <0.001, ****p <0.0001.

Figure Legend Snippet: Berberine and Taxifolin combined administration increased the protective effect against colitis in mice. (A) Body weight changes of mice after modeling and drug administration. (B–I) Body weight changes of mice at modeling and drug administration 7 th day to 14 th day. (J, K) The colon length changes in different treatment groups. (L) Disease activity index in different treatment groups. (M, N) The H&E staining and Histological scores in different treatment groups. *p <0.05; **p <0.01; ***p <0.001, ****p <0.0001.

Techniques Used: Activity Assay, Staining

Berberine and Taxifolin combined administration inhibited colon tissue cell apoptosis and improved colon mucosal structure and permeability. (A, B) TUNEL staining analysis the apoptotic cell proportion changes in each group. (C–F) The expression changes of apoptotic related protein including caspase3 p17/p19, Bax and Bcl-2 in each group by western blotting. (G, H) Representative immunofluorescence imaging and statistical analysis of occludin in each group. (I–K) The expression changes of occludin and ZO-1 in each group by western blotting. (L) FITC–dextran permeability assay showing changes of intestinal barrier function. (M, N) Representative immunofluorescence imaging and statistical analysis of MUC2 in each group. *p <0.05; **p <0.01; ***p <0.001, ****p <0.0001.

Figure Legend Snippet: Berberine and Taxifolin combined administration inhibited colon tissue cell apoptosis and improved colon mucosal structure and permeability. (A, B) TUNEL staining analysis the apoptotic cell proportion changes in each group. (C–F) The expression changes of apoptotic related protein including caspase3 p17/p19, Bax and Bcl-2 in each group by western blotting. (G, H) Representative immunofluorescence imaging and statistical analysis of occludin in each group. (I–K) The expression changes of occludin and ZO-1 in each group by western blotting. (L) FITC–dextran permeability assay showing changes of intestinal barrier function. (M, N) Representative immunofluorescence imaging and statistical analysis of MUC2 in each group. *p <0.05; **p <0.01; ***p <0.001, ****p <0.0001.

Techniques Used: Permeability, TUNEL Assay, Staining, Expressing, Western Blot, Immunofluorescence, Imaging, FITC-Dextran Permeability Assay

Berberine and Taxifolin combined administration ameliorated colon tissue inflammation and macrophage infiltration. (A–C) The mRNA expression changes of pro-inflammatory cytokines including IL-1β, iNOS, and TNF-α and IL-6 in each group by qRT-PCR. (D–H) The expression changes of pro-inflammatory cytokines including IL-1β, iNOS, and TNF-α and IL-6 in each group by western blotting. (I, J) Representative immunofluorescence imaging and statistical analysis of F4/80 in each group. *p <0.05; **p <0.01; ***p <0.001, ****p <0.0001.

Figure Legend Snippet: Berberine and Taxifolin combined administration ameliorated colon tissue inflammation and macrophage infiltration. (A–C) The mRNA expression changes of pro-inflammatory cytokines including IL-1β, iNOS, and TNF-α and IL-6 in each group by qRT-PCR. (D–H) The expression changes of pro-inflammatory cytokines including IL-1β, iNOS, and TNF-α and IL-6 in each group by western blotting. (I, J) Representative immunofluorescence imaging and statistical analysis of F4/80 in each group. *p <0.05; **p <0.01; ***p <0.001, ****p <0.0001.

Techniques Used: Expressing, Quantitative RT-PCR, Western Blot, Immunofluorescence, Imaging

Berberine and Taxifolin could bind with key molecular targets screened based on network pharmacology by molecular docking. (A, B) Molecular docking between Berberine or Taxifolin and NF-κB1 and Images showing specific binding sites and interaction patterns. (C, D) Molecular docking between Berberine or Taxifolin and NLRP3 and Images showing specific binding sites and interaction patterns. (E, F) Molecular docking between Berberine or Taxifolin and PPARγ and Images showing specific binding sites and interaction patterns. (G, H) Molecular docking between Berberine or Taxifolin and STAT3 and Images showing specific binding sites and interaction patterns. (I–K) Western blot analysis of NLRP3 and NF-κB signaling–related proteins in each group. (L) Western blot analysis of NLRP3 and NF-κB signaling–related proteins in vitro . **p <0.01; ***p <0.001, ****p <0.0001.

Figure Legend Snippet: Berberine and Taxifolin could bind with key molecular targets screened based on network pharmacology by molecular docking. (A, B) Molecular docking between Berberine or Taxifolin and NF-κB1 and Images showing specific binding sites and interaction patterns. (C, D) Molecular docking between Berberine or Taxifolin and NLRP3 and Images showing specific binding sites and interaction patterns. (E, F) Molecular docking between Berberine or Taxifolin and PPARγ and Images showing specific binding sites and interaction patterns. (G, H) Molecular docking between Berberine or Taxifolin and STAT3 and Images showing specific binding sites and interaction patterns. (I–K) Western blot analysis of NLRP3 and NF-κB signaling–related proteins in each group. (L) Western blot analysis of NLRP3 and NF-κB signaling–related proteins in vitro . **p <0.01; ***p <0.001, ****p <0.0001.

Techniques Used: Binding Assay, Western Blot, In Vitro

Image Search Results

Journal: Frontiers in Immunology

Article Title: Berberine-taxifolin co-administration attenuates inflammatory response and intestinal barrier injury via nf-κB/NLRP3 suppression in colitis

doi: 10.3389/fimmu.2025.1725084

Figure Lengend Snippet: Prediction of intersection targets shared by colitis and drugs (Berberine and Taxifolin) and biological function analysis. (A) The molecular targets of Berberine and Taxifolin and the molecular targets of colitis were searched through online databases. The Venn diagram was used to intersect the molecular targets of Berberine, Taxifolin and colitis. (B) The PPI was used to perform interaction analysis on 37 molecules. (C) The 37 molecular targets were visualized and clustered using Cytoscape software. (D) GO enrichment analysis was performed on 37 molecules. (E) KEGG enrichment analysis was performed on 37 molecules. (F) Re-clustering by MCODE (degree>5) in Cytoscape software. (G) The top 10 molecular targets among 37 molecules were screened using the EPC statistical method in Cytoscape software. (H) The top 10 molecular targets among 37 molecules were screened using the MCC statistical method in Cytoscape software.

Article Snippet: Taxifolin was obtained from MedChemExpress (HY-N0136, USA).

Techniques: Software

Journal: Frontiers in Immunology

Article Title: Berberine-taxifolin co-administration attenuates inflammatory response and intestinal barrier injury via nf-κB/NLRP3 suppression in colitis

doi: 10.3389/fimmu.2025.1725084

Figure Lengend Snippet: Berberine and Taxifolin combined administration increased the protective effect against colitis in mice. (A) Body weight changes of mice after modeling and drug administration. (B–I) Body weight changes of mice at modeling and drug administration 7 th day to 14 th day. (J, K) The colon length changes in different treatment groups. (L) Disease activity index in different treatment groups. (M, N) The H&E staining and Histological scores in different treatment groups. *p <0.05; **p <0.01; ***p <0.001, ****p <0.0001.

Article Snippet: Taxifolin was obtained from MedChemExpress (HY-N0136, USA).

Techniques: Activity Assay, Staining

Journal: Frontiers in Immunology

Article Title: Berberine-taxifolin co-administration attenuates inflammatory response and intestinal barrier injury via nf-κB/NLRP3 suppression in colitis

doi: 10.3389/fimmu.2025.1725084

Figure Lengend Snippet: Berberine and Taxifolin combined administration inhibited colon tissue cell apoptosis and improved colon mucosal structure and permeability. (A, B) TUNEL staining analysis the apoptotic cell proportion changes in each group. (C–F) The expression changes of apoptotic related protein including caspase3 p17/p19, Bax and Bcl-2 in each group by western blotting. (G, H) Representative immunofluorescence imaging and statistical analysis of occludin in each group. (I–K) The expression changes of occludin and ZO-1 in each group by western blotting. (L) FITC–dextran permeability assay showing changes of intestinal barrier function. (M, N) Representative immunofluorescence imaging and statistical analysis of MUC2 in each group. *p <0.05; **p <0.01; ***p <0.001, ****p <0.0001.

Article Snippet: Taxifolin was obtained from MedChemExpress (HY-N0136, USA).

Techniques: Permeability, TUNEL Assay, Staining, Expressing, Western Blot, Immunofluorescence, Imaging, FITC-Dextran Permeability Assay

Journal: Frontiers in Immunology

Article Title: Berberine-taxifolin co-administration attenuates inflammatory response and intestinal barrier injury via nf-κB/NLRP3 suppression in colitis

doi: 10.3389/fimmu.2025.1725084

Figure Lengend Snippet: Berberine and Taxifolin combined administration ameliorated colon tissue inflammation and macrophage infiltration. (A–C) The mRNA expression changes of pro-inflammatory cytokines including IL-1β, iNOS, and TNF-α and IL-6 in each group by qRT-PCR. (D–H) The expression changes of pro-inflammatory cytokines including IL-1β, iNOS, and TNF-α and IL-6 in each group by western blotting. (I, J) Representative immunofluorescence imaging and statistical analysis of F4/80 in each group. *p <0.05; **p <0.01; ***p <0.001, ****p <0.0001.

Article Snippet: Taxifolin was obtained from MedChemExpress (HY-N0136, USA).

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Immunofluorescence, Imaging

Journal: Frontiers in Immunology

Article Title: Berberine-taxifolin co-administration attenuates inflammatory response and intestinal barrier injury via nf-κB/NLRP3 suppression in colitis

doi: 10.3389/fimmu.2025.1725084

Figure Lengend Snippet: Berberine and Taxifolin could bind with key molecular targets screened based on network pharmacology by molecular docking. (A, B) Molecular docking between Berberine or Taxifolin and NF-κB1 and Images showing specific binding sites and interaction patterns. (C, D) Molecular docking between Berberine or Taxifolin and NLRP3 and Images showing specific binding sites and interaction patterns. (E, F) Molecular docking between Berberine or Taxifolin and PPARγ and Images showing specific binding sites and interaction patterns. (G, H) Molecular docking between Berberine or Taxifolin and STAT3 and Images showing specific binding sites and interaction patterns. (I–K) Western blot analysis of NLRP3 and NF-κB signaling–related proteins in each group. (L) Western blot analysis of NLRP3 and NF-κB signaling–related proteins in vitro . **p <0.01; ***p <0.001, ****p <0.0001.

Article Snippet: Taxifolin was obtained from MedChemExpress (HY-N0136, USA).

Techniques: Binding Assay, Western Blot, In Vitro

Review

Structured Review

Images

1) Product Images from "Berberine-taxifolin co-administration attenuates inflammatory response and intestinal barrier injury via nf-κB/NLRP3 suppression in colitis"

Similar Products

Image Search Results